Personal Information. Language Skills. Address. Telephone. . Language Read Write Speak Understand English Yes Yes Yes Yes French Yes Yes Yes Yes

Size: px
Start display at page:

Download "Personal Information. Language Skills. Address. Telephone. Email. Language Read Write Speak Understand English Yes Yes Yes Yes French Yes Yes Yes Yes"

Transcription

1 Protected when completed This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted. It is strictly forbidden to submit this draft version to an organization that is not a member of the CCV. The complete list of CCV members is available at Personal Information Identification Correspondence language: English Sex: Male Date of Birth: 8/25 Canadian Residency Status: Canadian Citizen Country of Citizenship: Canada Language Skills Language Read Write Speak Understand English Yes Yes Yes Yes French Yes Yes Yes Yes Address The primary address is denoted by (*) Courier Primary Affiliation (*) CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavilion, Rm Montréal H2W 1T7 Canada, Quebec CRCHUM Hôtel-Dieu 3850 St. Urbain Street Masson Pavilion, Rm Montréal H2W 1T7 Canada, Quebec Telephone The primary telephone is denoted by (*) Fax Work extension: Work (*) extension: The primary is denoted by (*) Work (*) 1

2 User Profile DRAFT Disciplines Trained In: Endocrinology Research Disciplines: Endocrinology Areas of Research: Diabetes, Hormonal Regulation, Metabolism, Nutrition, Pharmacoepidemiology Fields of Application: Biomedical Aspects of Human Health, Pathogenesis and Treatment of Diseases Research Specialization Keywords: carbohydrate metabolism, complications, diabetes melllitus, glucagon secretion/action, glucose turnover, insulin secretion/action, isotopic technique, nutrition/ treatment, organ perfusion, prevention Education Degrees 1970/7-1975/7 Diploma - Certification - Endocrinology - McGill University - Completed 1967/7-1968/7 Doctorate - LMCC - M.D. - Endocrinologist - Medical Research Council of Canada - Completed 1963/9-1967/7 Doctorate - M.D. - Medical Doctor - Université Laval - Completed 1961/9-1963/7 Bachelor's - B.A. - Chemistry - Sainte-Anne - Completed Employment Academic Work Experience 1992/10 - Chief, Research Group on Diabetes and Metabolic Regulation CRCHUM 1992/7 - Full Professor Université de Montréal - Médecine 1980/7 - Endocrinologist CHUM Affiliations The primary affiliation is denoted by (*) (*) 1992/7 - Full Professor - Médecine - Université de Montréal Research Funding History Awarded 2012/5-2019/5 The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND). : Jean-Louis Chiasson 2

3 2012/6-2017/6 2011/4-2016/4 2010/1-2015/1 2012/5-2014/5 2011/7-2013/7 DRAFT 2012/5-2019/5 Clinical randomized trial Eli Lilly Canada Inc. Total Funding: (Canadian dollar) Determinants of increased risk of cardio-vascular diseases in HIV-infected individuals. 2012/6-2017/6 Subvention d'équipe: VIH/sida et comorbidités Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) Étude de phase IV multicentrique, à répartition aléatoire et à double insu avec contrôle par placebo visant à évaluer l effet de la saxagliptine sur l incidence du décès d origine cardiovasculaire, de l infarctus du myocarde ou de l AVC ischémique.. Co-investigator : Sophie Bernard 2011/4-2016/4 AstraZeneca Canada Inc. Total Funding: (Canadian dollar) TECOS: A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control on mono- or dual combination on oral... : Chiasson, Jean-Louis;Étude multicentrique; 2009/ /11 Clinical trial Merck & Co. Inc Total Funding: (Canadian dollar) The impact of LY versus insulin glargine for patients with type 1 diabetes mellitus treated with preprandial insulin lispro: a double-blind, randomized, 52-week study. The IMAGINE 3 Study. Co-investigator : Sophie Bernard 2012/5-2014/5 Clinical randomized trial Eli Lilly Canada Inc. Total Funding: (Canadian dollar) A 24-week, multicenter, international, randomized (1:1), parallel-group, openlabel, comparative study of insulin glargine versus liraglutide in insulin-naive patients with type 2 diabetes trated with oral agents and not adequately controlled with... Co-investigator : Sophie Bernard 3

4 2012/7-2013/6 Applicant 2012/5-2013/5 2010/3-2013/3 2011/2-2013/2 2011/4-2012/4 DRAFT 2011/7-2013/7 Sanofi-aventis Total Funding: (Canadian dollar) Quelle est l'évidence justifiant la recommandation d'utiliser 1 mg de glucagon pour corriger l'hyperglycémie sévère chez le sujet avec diabète de type 1? Applicant : Jean-Louis Chiasson 2012/7-2013/6 Diabetes Québec Total Funding: (Canadian dollar) 6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus both plus mealtime insulin in patients with type 2 diabetes mellitus with a 6-mo safety extension Co-investigator : Sophie Bernard 2012/5-2013/5 Clinical randomized trial Sanofi-aventis Total Funding: (Canadian dollar) Autogestion du diabète et dépression : Marie-Dominique Beaulieu 2010/3-2013/3 Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) A randomized, doule-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of canagliflozin compared with placebo in the treatment of older subjects with type 2 diabetes mellitus inadequately.. Co-investigator : Sophie Bernard 2011/2-2013/2 Clinical trial, Janssen Inc. Janssen-Ortho Inc. Total Funding: (Canadian dollar) A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI (10 mg and 25 mg once daily) and sitagliptin (100 mg once daily) given for a minimum of 76 weeks (incl. 24 weeks of preceding trial)... Co-investigator : Sophie Bernard 4

5 2010/1-2011/1 DRAFT 2011/4-2012/6 Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: (Canadian dollar) VIH et prévention des comorbidités: Adapter et valider une intervention virtuelle visant à réduire les facteurs de risque liés aux maladies cardiovasculaires et au diabète chez les personnes vivant avec le VIH. : Josée Coté 2010/1-2011/1 Operating grant Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) Completed 2011/1-2012/1 2007/7-2011/7 2010/9-2011/3 2010/1-2011/1 A randomized trial evaluating the effect of liraglutide versus insulin glargine on hepatic steatosis as measured by MRI and MRS in metformin-treated patients with type 2 diabetes. : An Tang 2010/1-2011/1 RSNA R&E Foundation Fonds de la Recherche en Santé du Québec (FRSQ) Total Funding: (Canadian dollar) Rigorous evaluation and integration medicine in aboriginal diabetes care. : Pierre Haddad 2007/7-2011/7 Team in Traditional Aboriginal Plants Against Diabetes Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control. Co-investigator : Sophie Bernard 2010/9-2011/3 Clinical trial, Boehringer Ingelheim Boehringer Ingelheim Total Funding: (Canadian dollar) Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique... : An Tang 5

6 2010/1-2011/1 2007/7-2010/7 2009/1-2010/1 2007/7-2009/7 2007/6-2008/12 DRAFT 2010/1-2011/1 Diabetes Québec Total Funding: (Canadian dollar) Essai randomisé du liraglutide versus l'insuline glargine sur la stéatose hépatique mesurée par résonance magnétique chez les patients atteints de diabète de type 2 traités à la metformine. : Tang, An;Dr Jean-Louis Chiasson 2010/1-2011/1 Canadian Heads of Academic Radiology (CHAR) Total Funding: 7500 (Canadian dollar) Estimating the prevalence of diabetes using multiple tests: A validation of the national diabetes surveillance system definition. : Elham Rahme 2007/7-2010/7 INMD Diabetes Surveillance Systems/CIHR Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) Innovation in cardiovascular imaging and image-guided therapy to improve patient management. : Gilles Soulez 2009/1-2010/1 FCI Canada Foundation for Innovation (CFI) Total Funding: (Canadian dollar) The DREAM On Study (an observational study). Diabetes REduction Assessment with ramipril and rosiglitazone Medication Ongoing evaluation. : Hertzel C. Gerstein 2007/7-2008/7 Clinical Trial Canadian Institutes of Health Research (CIHR) Total Funding: (Canadian dollar) A multicenter, randomized, double-blind study to evaluate the safety and efficacy of the addition of sitagliptin (MK-0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination... Co-investigator : Rémi Rabasa-Lhoret 2007/6-2008/12 Merck Frosst Canada Inc Total Funding: (Canadian dollar) 6

7 2007/ /11 A 12-week, randomized, multicenter, double-blind, placebo-controlled study, assessing the safety and efficacy of ID1101 in obese patients Co-investigator : Rémi Rabasa-Lhoret 2007/ /11 Innodia Inc. Total Funding: (Canadian dollar) Activities Supervisory Activities Student/Postdoctoral Supervision Co-Supervisor Supervisor Co-Supervisor Co-Supervisor Supervisor Supervisor Sima Aurelia - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: L acide rétinoïque dans l obésité et le diabète de type 2 Present Position: Ph.D. Student Lorena Iglesias - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2009/1 Student Degree Received Date: 2011/6 Project Description: Évaluation d'un prototype d'un détecteur de glucose photonique. Present Position: public sector Constantin Manolescu Daniel - Doctorate - Université de Montréal - In Progress Student Degree Start Date: 2009/1 Student Degree Expected Date: 2013/6 Project Description: Retinoic acid and insulin resistance in the development of type 2 diabetes Present Position: Ph.D. Student Janie Houle, - Post-doctorate - UQAM - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2011/12 Project Description: Impact de la dépression sur les comportements d'autogestion du diabète Present Position: academic sector Zebdi Samia - Bachelor's - UQTR - Completed Student Degree Start Date: 2007/1 Student Degree Received Date: 2007/4 Project Description: Le rôle de l'hyperglycémie post-prandiale dans les complications coronariennes Brindisi Marie-Claude - Post-doctorate - CHU Bocage (Dijon, France) - Completed Student Degree Start Date: 2004/12 Student Degree Received Date: 2007/4 Project Description: Effets de l'acarbose et du répaglinide sur le stress oxydatif... Present Position: Endocrinologist, Dijon (France) 7

8 Supervisor Supervisor Co-Supervisor Supervisor Supervisor Geneviève Beauregard, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/1 Project Description: Étude de la régulation de l'expression des gènes par l'insuline et le glucose Demiana Ekladous, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2003/1 Student Degree Received Date: 2005/6 Project Description: Hepatic resistance to glucagon Amélie Pelletier, - Doctorate - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2006/6 Project Description: Regulation of glucose uptake in cardiomyocytes Present Position: Research Coordinator Sandra Bérubé, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 2000/6 Student Degree Received Date: 2003/7 Project Description: Insulin sensitivity in a healthy population Present Position: private sector Yamina Boukhors, - Master's Thesis - Université de Montréal - Completed Student Degree Start Date: 1998/9 Student Degree Received Date: 2003/8 Project Description: Use of information technology for management of ITT in type 1 diabetes Present Position: other International Collaboration Activities Member Contributions Presentations United Kingdom Activity Description: The Acarbose Cardiovascular Evaluation (ACE) Trial "Prevention of diabetes: Are we there yet?", At the Heart of Diabetes. An Essential Primer for Cardiovascular Renal and Metabolic Risk Reduction in Diabetes., Canada, Ontario, Toronto Invited?: Yes Vincent Poitout, "La glucotoxicité et la lipotoxicité dans le développement du diabète de type 2 et des complications vasculaires : approches fondamentales et cliniques.", Séminaire de la direction scientifique, Département de médecine, CHUM, Canada, Quebec, Montreal Invited?: Yes 8

9 "Lignes directrices de pratique clinique pour la prévention et le traitement du diabète 2013", Endocrine Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montreal Invited?: Yes "Pré-diabète: fault-il le traiter?", Congrès de la Société Francophone du diaète 2013, France, Montpellier Invited?: Yes "Treatment of diaetes mellitus and the vascular complications.", SANOFI Guest speaker, Canada, Quebec, Laval Invited?: Yes "Treating postprandial hyperglycaemia for the prevention of cardiovascular disease.", National Atherosclerosis and Cardiometabolic Forum, Canada, Ontario, Toronto Invited?: Yes "Les complications vasculaires du diabète de type 2: peut-on les freiner?", Eli Lilly Guest Speaker, Canada, Quebec, Montreal Invited?: Yes "Mieux traiter les troubles métaboliques des patients VIH en 2012.", Dépistage et gestion du diabète chez le patient VIH, Canada, Quebec, Montréal Invited?: Yes "Treating postprandial plasma glucose for the prevention of diabetes and CVD: the STOP-NIDDM Trial.", Bayer Scientific Meeting., China, Beijing : Bayer HealthCare AG "La glycémie postprandiale et le risque cardiovasculaire.", Bayer Scientific Symposium, Tunisia, Djerba : Bayer AG "Le rôle des incrétines dans le diabète de type 2.", 21e Congrès National d'endocrinologie de la Société Tunisienne d'endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis : Bayer AG "Le traitement de l'hyperglycémie postprandiale pour la prévention du diabète et des complications cardiovasculaires.", 21e Congrès National d'endocrinologie de la Société Tunisienne d'endocrinologie, Diabète et Maladies Métaboliques, Tunisia, Tunis : Bayer AG - 0 9

10 "La glycémie et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Tunis : Bayer AG "La glycémie postprandiale et le risque cardiovasculaire.", Bayer Guest Speaker, Tunisia, Sfax : Bayer AG "Disposition index and the conversion of IGT to diabetes mellitus: The STOP- NIDDM Trial.", International Diabetes Federation 2011 (IDF 2011). Session: Insulin resistance in young and old., United Arab Emirates, Dubai "Le rôle de la microflore intestinale dans le développement de l'obésité.", Guest Speaker Sanofi, Scientific Grand Round, Division of Endocrinology, CHUM, Canada, Quebec, Montréal "Glucose control and cardiovascular disease.", ACE Regional Meeting, Speaker Tour, China, Guangzhou "Glucose control and cardiovascular disease.", ACE Regional Meeting, Speaker Tour., China, Hangzhou "Traiter l'hyperglycémie postprandiale pour la prévention du diabète et des complications vasculaires.", Sanofi Aventis Guest speaker, Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal "Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Workshop., France, Nice "How to achieve safe and long-term glycaemic control with cardiovascular benefits.", Bayer Schering Pharma, 2nd Cardiovascular Risk Management Symposium. The Challenge of Cardiovascular Disease Prevention., France, Nice "CSN Debate: Hemoglobin A1C should be normalized with intensive insulin therapy to prevent macro- and microvascular disease in type 2 diabetes. Affirmative: Jean-Louis Chiasson, Negative: Richard Gilbert", Canadian Society of Nephrology Annual General Meeting 2010., Canada, Quebec, Montreal "L'hyperglycémie post-prandiale, son rôle délétère et sa prise en charge.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger "La prévention du diabète de type 2.", Congrès annuel de la Société Algérienne de Diabétologie., Algeria, Alger 10

11 "Evidence for CV benefits with acarbose intervention.", Bayer Schering Pharma Asia-Pacific Cardiovascular Risk Management Expert Workshop., Taiwan, Province of China, Taipei "Effects of oral diabetic drugs on CVD.", Bayer Schering Pharma Asia-Pacific ACE Speaker. Training Workshop., Taiwan, Province of China, Taipei "Atteindre les cibles en diabète: Nouvelles options pour l'insulinothérapie.", Sanofi Aventis Guest Speaker. Division of Endocrinology, Montreal Jewish Hospital., Canada, Quebec, Montreal "Guest speaker and Chairman: Intervention multifactorielle dans le traitement du diabète de type 2.", Optimizing long-term glycemic control in type 2 diabetes: Overcoming a progressive pathophysiology with incretin therapie (WorldWIDE), Symposium during the 20th IDF World Diabetes Congress., Canada, Quebec, Montreal "Debate on Primary prevention programmes for diabetes: lifestyle versus drugs - Drugs.", 20th IDF World Diabetes Congress., Canada, Quebec, Montreal "Guest speaker and Chairman. Glucose lowering interventions in diabetes and CVD - lessons from outcome studies.", Bayer Healthcare Satellite Symposium, 20th IDF World Diabetes Congress, Canada, Quebec, Montreal "Traiter l'hyperglycémie postprandiale pour diminuer le risque de diabète et de ses complications vasculaires.", Bayer Healthcare Meet the Expert Session, 20th IDF World Diabetes Congress., Canada, Quebec, Montreal "Postprandial peak reduction and its implication in the prevention of CV risk and diabetes.", Congress of Obesity, Metabolic Syndrome and Prediabetes., Venezuela, Bolivarian Republic of, Caracas "La prévention du diabète de type 2 et de ses complications.", Guest speaker Eli Lilly, Division of Endocrinology., Canada, New Brunswick, Moncton "Stratégies de sensibilisation à l'insuline et d'apport d'insuline dans le traitement du diabète de type 2. Quand et pourquoi?", Diabetes Forum., Canada, Quebec, Montreal "Postprandial plasma glucose as a risk factor for cardiovascular disease.", Endocrine Grand Round, Division of Endocrinology, University of Toronto., Canada, Ontario, Toronto "The benefits of early insulin as opposed to oral hypoglycemic agents in type 2 diabetes.", Canadian Society of Endocrinology and Metabolism., Canada, Ontario, Toronto

12 "L'insulinothérapie : Initiation pratique et nouvelles insulines.", SSVQ Symposium (Société des sciences vasculaires du Québec) - Le diabète: démystifier l'insulinothérapie et les nouveaux hypoglycémiants oraux., Canada, Quebec, Montreal Interviews and Media Relations Broadcast Interviews Publications PubMed Articles Type 2 diabetes "Les docteurs" - Radio-Canada Chiasson JL, "Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.", Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 12 Suppl 1 PubMed ID: Althouse AD, Abbott JD, Sutton-Tyrrell K, Forker AD, Lombardero MS, Buitrón LV, Pena-Sing I, Tardif JC, Mori Brooks M,, "Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care PubMed ID: Leong A, Dasgupta K, Chiasson JL, Rahme E, "Estimating the Population Prevalence of Diagnosed and Undiagnosed Diabetes.", Diabetes care PubMed ID: Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK,, "Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revasc", Journal of the American College of Cardiology, 61(17) PubMed ID: Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V, "Risk factor control for coronary artery disease secondary prevention in large randomized trials.", Journal of the American College of Cardiology, 61(15) PubMed ID: Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J,, "Determinants of successful glycemic control among participants in the BARI 2D Trial: A Post-hoc Analysis.", Journal of diabetes and its complications PubMed ID:

13 Wolever, T.M.S., Gibbs, A.L., Chiasson, J.L., Connelly, P.W., Josse, R.G., Leiter, L.A., Maheux, P., Rabasa-Lhoret, R., Rodger, N.W., Ryan, E.A., "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", Nutr. Metab. Cardiovasc. Dis., 23 PubMed ID: Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V,, "Strategies for multivessel revascularization in patients with diabetes.", The New England journal of medicine, 367(25) PubMed ID: Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R, "Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).", Diabetes therapy : research, treatment and education of diabetes and related disorders, 3(1) PubMed ID: Hanefeld M, Pistrosch F, Koehler C, Chiasson JL, "Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial.", Journal of hypertension, 30(7) PubMed ID: Henderson M, Baillargeon JP, Rabasa-Lhoret R, Chiasson JL, Hanley J, Lambert M, "Estimating insulin secretion in youth using simple indices derived from the oral glucose tolerance test.", Diabetes & metabolism PubMed ID: Wolever TM, Gibbs AL, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "Altering source or amount of dietary carbohydrate has acute and chronic effects on postprandial glucose and triglycerides in type 2 diabetes: Canadian trial of Carbohydrates in Diabetes (CCD).", Nutrition, metabolism, and cardiovascular diseases : NMCD PubMed ID: Broderick TL, El Midaoui A, Chiasson JL, Wang D, Jankowski M, Gutkowska J, "The effects of exercise training on #-butyrobetaine hydroxylase and novel organic cation transporter-2 gene expression in the rat.", Applied physiology, nutrition, and metabolism = Physiologie appliquée, nutrition et métabolisme, 36(6) PubMed ID: "Incidence of diabetes following ramipril or rosiglitazone withdrawal.", Diabetes care, 34(6) PubMed ID: Gerstein HC, Mohan V, Avezum A, Bergenstal RM, Chiasson JL, Garrido M, MacKinnon I, Rao PV, Zinman B, Jung H, Joldersma L, Bosch J, Yusuf S, "Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.", Diabetologia, 54(3) PubMed ID:

14 Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW,, "The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", Diabetes care, 34(2) PubMed ID: Henderson M, Rabasa-Lhoret R, Bastard JP, Chiasson JL, Baillargeon JP, Hanley JA, Lambert M, "Measuring insulin sensitivity in youth: How do the different indices compare with the gold-standard method?", Diabetes & Metabolism, 37(1) PubMed ID: Tuomilehto J, Lindström J, Hellmich M, Lehmacher W, Westermeier T, Evers T, Brückner A, Peltonen M, Qiao Q, Chiasson JL, "Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-the STOP-NIDDM riskscore.", Diabetes research and clinical practice, 87(2) PubMed ID: Chiasson JL, "Early insulin use in type 2 diabetes: what are the cons?", Diabetes care, 32 Suppl 2 PubMed ID: de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, Macmahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M,, "Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.", Diabetologia, 52(11) PubMed ID: Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J,, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F, "Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.", Diabetes care, 32(11) PubMed ID: Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE, "A randomized trial of therapies for type 2 diabetes and coronary artery disease.", The New England journal of medicine, 360(24) PubMed ID: Hammana I, Coderre L, Potvin S, Costa M, Berthiaume Y, Lavoie A, Chiasson JL, Levy E, Rabasa-Lhoret R, "Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study.", Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 8(2) PubMed ID:

15 Pop-Busui R, Lu J, Lopes N, Jones TL,, "Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.", Journal of the peripheral nervous system : JPNS, 14(1) PubMed ID: Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL, "Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.", Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, 6(1) PubMed ID: Sreenan S, Virkamäki A, Zhang K, Hansen JB,, "Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.", International journal of clinical practice, 62(12) PubMed ID: Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, Chiasson JL, Coderre L, Rabasa-Lhoret R, "No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes.", Diabetes & metabolism, 34(6 Pt 1) PubMed ID: Wolever TM, Mehling C, Chiasson JL, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial.", Diabetologia, 51(9) PubMed ID: "Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.", American heart journal, 156(3) PubMed ID: Ekladous D, Mehdi MZ, Costa M, Srivastava AK, Chiasson JL, Coderre L, "Tissue- and fibre-specific modifications of insulin-signalling molecules in cardiac and skeletal muscle of diabetic rats.", Clinical and experimental pharmacology & physiology, 35(8) PubMed ID: Cloutier G, Zimmer A, Yu FT, Chiasson JL, "Increased shear rate resistance and fastest kinetics of erythrocyte aggregation in diabetes measured with ultrasound.", Diabetes care, 31(7) PubMed ID: Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.", The New England journal of medicine, 358(24) PubMed ID:

16 Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S, "Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.", Diabetes care, 31(5) PubMed ID: Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA, "The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of lowglycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein.", The American journal of clinical nutrition, 87(1) PubMed ID: Chiasson JL, "Prevention of Type 2 diabetes: fact or fiction?", Expert opinion on pharmacotherapy, 8(18) PubMed ID: Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, Lavoie A, Lévesque R, Perrier J, Poisson D, Karelis AD, Chiasson JL, Rabasa- Lhoret R, "Increased glucose excursion in cystic fibrosis and its association with a worse clinical status.", Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 6(6) PubMed ID: Godbout A, Chiasson JL, "Who should benefit from the use of alphaglucosidase inhibitors?", Current diabetes reports, 7(5) PubMed ID: Patel A,, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.", Lancet, 370(9590) PubMed ID: Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, Connelly PW, Corey PN, El-Sohemy A, "Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDLcholesterol and apo A-I concentrations.", The American journal of clinical nutrition, 86(3) PubMed ID: Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, Chiasson JL, Coderre L, Rabasa-Lhoret R, "Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis.", Diabetes & metabolism, 33(3) PubMed ID:

17 Chui MH, Papanikolaou Y, Fontaine-Bisson B, Turcotte J, Wolever TM, El- Sohemy A, Chiasson JL, Rabasa-Lhoret R, Maheux P, Ryan E, Greenwood CE, "The TNF-alpha-238G > a single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes.", Behavioral neuroscience, 121(3) PubMed ID: Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, El-Sohemy A, "Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.", Metabolism: clinical and experimental, 56(5) PubMed ID: Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", Diabetes, 56(4) PubMed ID: Meugnier E, Faraj M, Rome S, Beauregard G, Michaut A, Pelloux V, Chiasson JL, Laville M, Clement K, Vidal H, Rabasa-Lhoret R, "Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects.", Diabetes, 56(4) PubMed ID: Pelletier A, Tardif A, Gingras MH, Chiasson JL, Coderre L, "Chronic exposure to ketone bodies impairs glucose uptake in adult cardiomyocytes in response to insulin but not vanadate: the role of PI3-K.", Molecular and cellular biochemistry, 296(1-2) PubMed ID: Brindisi MC, Hahn J, Chiasson JL, Rabasa-Lhoret R, "Under-utilization of capillary glucose monitoring by type 2 diabetic patients.", Diabetes research and clinical practice, 75(1) PubMed ID: Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR, "Effect of ramipril on the incidence of diabetes.", The New England journal of medicine, 355(15) PubMed ID: Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR, "Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.", Lancet, 368(9541) PubMed ID: Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.", Journal of molecular medicine (Berlin, Germany), 84(8) PubMed ID:

18 Andrulionyte L, Peltola P, Chiasson JL, Laakso M,, "Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.", Diabetes, 55(7) PubMed ID: Sobel BE,, "Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities.", The American journal of cardiology, 97(12A) PubMed ID: Albu J, Gottlieb SH, August P, Nesto RW, Orchard TJ,, "Modifications of coronary risk factors.", The American journal of cardiology, 97(12A) PubMed ID: Barsness GW, Gersh BJ, Brooks MM, Frye RL,, "Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: Steiner G,, "Statement of the problem.", The American journal of cardiology, 97(12A) PubMed ID: Magee MF, Isley WL,, "Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ,, "Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.", The American journal of cardiology, 97(12A) PubMed ID: Hlatky MA, Melsop KA, Boothroyd DB,, "Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.", The American journal of cardiology, 97(12A) PubMed ID: Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J,, "Homocysteine lowering with folic acid and B vitamins in vascular disease.", The New England journal of medicine, 354(15) PubMed ID: Brindisi MC, Rabasa-Lhoret R, Chiasson JL, "Postprandial hyperglycaemia: to treat or not to treat?", Diabetes & metabolism, 32(2) PubMed ID: El Midaoui A, Chiasson JL, Tancrède G, Nadeau A, "Physical training reverses the increased activity of the hepatic ketone body synthesis pathway in chronically diabetic rats.", American journal of physiology. Endocrinology and metabolism, 290(2) PubMed ID:

19 Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S,, "Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.", The Canadian journal of cardiology, 22(1) PubMed ID: Journal Articles 2011/1 Published First Listed Author 2008/ Published Co-Author 2008/ Published Co-Author 2006/ Published First Listed Author Chiasson, J.L. and Bernard, S., "Reducing cardiovascular risk factors in patients with pre-diabetes.", Diabetes Management, 1, Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Screening for type 1 and type 2 diabetes.", Can. J. Diabetes, 32(Suppl 1), S14-S16 Ur, E., Chiasson, J.L., Ransom, T., Rowe, R., "Prevention of diabetes.", Can. J. Diabetes, 32(Suppl 1), S17-S19 Chiasson, J.L., "Pharmacological and surgical intervention for the prevention of diabetes.", Nestlé Nutrition Workshop Ser. Clin. Perform. Programme, 11, Book Chapters 2012/ In Press First Listed Author 2012/ In Press Last Author "Decreasing postprandial plasma glucose in subjects with IGT using an # (alpha)-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: The STOP-NIDDM Trial.", Prevention of type 2 diabetes; From Science to Therapies, LeRoith, D., Ed., Springer Science Authors: Chiasson, J.L., Laakso, M., and Hanefeld, M.: "Prevention of type 2 diabetes (chapter 38).", Diabetes in America, NIH Authors: Knowler, B., Chiasson, J.L. Clinical Care Guidelines "2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada" Description / Contribution Value: The purpose of this review was to determine that there was no salient information missing, no conflicting recommendations, and that the recommendations are generally applicable to clinical practice. 19

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief

Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness

More information

Diagnosis, classification and prevention of diabetes

Diagnosis, classification and prevention of diabetes Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3

More information

Diabetes mellitus. Lecture Outline

Diabetes mellitus. Lecture Outline Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized

More information

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D. TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type

More information

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS - Summary CHRONIC COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS - Epidemiological study - PhD Manager: Professor PhD.

More information

Introduction. Pathogenesis of type 2 diabetes

Introduction. Pathogenesis of type 2 diabetes Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

Diabetes is a. A case for prevention of type 2 diabetes mellitus

Diabetes is a. A case for prevention of type 2 diabetes mellitus A case for prevention of type 2 diabetes mellitus Joseph Cook, DO Diabetes is a disease that has reached epidemic proportions in the United States and around the world. This is troubling because, as bad

More information

Telephone: 514-878-2691 Email: parent.nicole@rcgt.com

Telephone: 514-878-2691 Email: parent.nicole@rcgt.com NICOLE PARENT, RN PHD Telephone: 514-878-2691 Email: parent.nicole@rcgt.com CAREER PROFILE Nicole Parent, RN, PhD is a Senior Consultant in s Strategy and Performance Consulting Group. She is also a nurse

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

Type II diabetes: How to use the new oral medications

Type II diabetes: How to use the new oral medications Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.

More information

Type 2 Diabetes Media Fact Sheet

Type 2 Diabetes Media Fact Sheet Type 2 Diabetes Media Fact Sheet 1. Type 2 diabetes: Facts & figures 2. What is type 2 diabetes? 3. Risk factors for type 2 diabetes 4. Complications associated with type 2 diabetes 5. The socio-economic

More information

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence

More information

Present and Future of Insulin Therapy: Research Rationale for New Insulins

Present and Future of Insulin Therapy: Research Rationale for New Insulins Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010

David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes

More information

Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW

Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim

More information

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.

More information

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.

Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word

More information

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL

IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL 464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized

More information

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United

More information

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What

More information

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005

Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,

More information

Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes

Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth

More information

The majority of patients destined to develop

The majority of patients destined to develop RATIONALE FOR DIFFERENT AND EFFECTIVE TREATMENT APPROACHES IN TYPE 2 DIABETES * Martin J. Abrahamson, MD ABSTRACT The most common cause of mortality in diabetes is macrovascular disease, specifically coronary

More information

Harmony Clinical Trial Medical Media Factsheet

Harmony Clinical Trial Medical Media Factsheet Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual

More information

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine Graduate Certificate in Metabolic & Nutritional Medicine Graduate Certificate Metabolic & Nutritional Medicine Purpose

More information

Effects of macronutrients on insulin resistance and insulin requirements

Effects of macronutrients on insulin resistance and insulin requirements Effects of macronutrients on insulin resistance and insulin requirements Dr Duane Mellor RD Assistant Professor in Dietetics, The University of Nottingham, UK Outline of Discussion Issues of determining

More information

COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL

COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval

More information

Prevention of Cardiovascular Disease in Children with Diabetes

Prevention of Cardiovascular Disease in Children with Diabetes Prevention of Cardiovascular Disease in Children with Diabetes Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine The Children s Hospital Anschutz Medical Campus

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)

More information

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages

More information

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary

More information

Baskets of Care Diabetes Subcommittee

Baskets of Care Diabetes Subcommittee Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level

More information

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing

More information

DM Management in Elderly- What are the glucose targets?

DM Management in Elderly- What are the glucose targets? DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures

More information

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours

Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,

More information

Diabetes Medications: Insulin Therapy

Diabetes Medications: Insulin Therapy Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta

More information

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:

More information

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body. International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.

More information

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening

More information

Jill Malcolm, Karen Moir

Jill Malcolm, Karen Moir Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are

More information

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2

More information

New in Diabetes. Diabetes is becoming more common. By the. What s. Presented at McMaster University, Hamilton, Ontario, October 2001.

New in Diabetes. Diabetes is becoming more common. By the. What s. Presented at McMaster University, Hamilton, Ontario, October 2001. Focus on CME at McMaster University What s New in Diabetes By Sarah Capes, MD, FRCPC Presented at McMaster University, Hamilton, Ontario, October 2001. Diabetes is becoming more common. By the year 2025,

More information

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types

Insulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by

More information

Pathophysiology of Type 2 Diabetes and Its Treatment Policy

Pathophysiology of Type 2 Diabetes and Its Treatment Policy Research and Reviews Pathophysiology of Type 2 Diabetes and Its Treatment Policy JMAJ 53(1): 41 46, 2010 Kohei KAKU* 1 Abstract Impaired insulin secretion and increased insulin resistance, the main pathophysiological

More information

THE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY

THE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY Analele UniversităŃii din Oradea Fascicula:Ecotoxicologie, Zootehnie şi Tehnologii de Industrie Alimentară, 2012 THE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY *University of

More information

Improving primary care management of depression in adults with comorbid chronic illnesses

Improving primary care management of depression in adults with comorbid chronic illnesses Executive summary of current research Improving primary care management of depression in adults with comorbid chronic illnesses Principal Investigator Jane McCusker, MD DrPH Co-Investigators Martin Cole,

More information

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME 1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome

More information

Intensive Insulin Therapy in Diabetes Management

Intensive Insulin Therapy in Diabetes Management Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition

More information

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used

More information

Abdulaziz Al-Subaie. Anfal Al-Shalwi

Abdulaziz Al-Subaie. Anfal Al-Shalwi Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied

More information

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de

More information

Deakin Research Online

Deakin Research Online Deakin Research Online This is the published version: Cameron, Adrian J., Shaw, J.E. and Zimmet, P.Z. 2003, Diabetes, in Diabetes and kidney disease : time to act, nternational Diabetes Federation, Brussels,

More information

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc. PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd

linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of

More information

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:

More information

Glycemic Control of Type 2 Diabetes Mellitus

Glycemic Control of Type 2 Diabetes Mellitus Bahrain Medical Bulletin, Vol. 28, No. 3, September 2006 Glycemic Control of Type 2 Diabetes Mellitus Majeda Fikree* Baderuldeen Hanafi** Zahra Ali Hussain** Emad M Masuadi*** Objective: To determine the

More information

Britni Hebert, MD PGY-1

Britni Hebert, MD PGY-1 Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,

More information

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections. National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.

More information

I. Research Proposal. 1. Background

I. Research Proposal. 1. Background Sample CFDR Research Proposal I. Research Proposal 1. Background Diabetes has been described as the the perfect epidemic afflicting an estimated 104 million people worldwide (1). By 2010, this figure is

More information

Insulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB

Insulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising

More information

The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014

The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014 Introduction The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014 The prevalence of type 2 diabetes is reaching epidemic proportions with more than 9.3% of adults in

More information

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children

More information

Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System

Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment Bruce Latham, M.D. Endocrine Specialists Greenville Health System Objectives for this presentation - Understand the thrifty genotype

More information

Cochrane Quality and Productivity topics

Cochrane Quality and Productivity topics Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices

More information

Tunis_2012-CCP lecture

Tunis_2012-CCP lecture Hyperlipidemia and Prevention New ESC Guidelines Implications for the practicing cardiologist Les 9 Journées Tuniso Européennes de Cardiologie Pratique les 28, 29 et 30 Juin 2012 Per Anton Sirnes, Norway

More information

Type 2 Diabetes. Tabinda Dugal GP Day 4/05/16

Type 2 Diabetes. Tabinda Dugal GP Day 4/05/16 Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes

More information

Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care

Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care This advice has been developed to help GPs with shared care of patients with Non- Alcohol

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

Synthesis of ECT evidence

Synthesis of ECT evidence Efficacy Synthesis of ECT evidence Risk Reference : Agence d évaluation des technologies et des modes d intervention en santé (AETMIS). The use of electroconvulsive therapy in Québec. Report prepared by

More information

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223- Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and

More information

Cardiovascular Effects of Drugs to Treat Diabetes

Cardiovascular Effects of Drugs to Treat Diabetes Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:

More information

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:

More information

In many diabetes units, people with type

In many diabetes units, people with type Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for

More information

Type 2 Diabetes in Youth A Road Less Travelled

Type 2 Diabetes in Youth A Road Less Travelled Type 2 Diabetes in Youth A Road Less Travelled Julie Halipchuk, RN MN CDE Clinical Nurse Specialist Diabetes Education Resource for Children & Adolescents, Winnipeg, MB Objectives Discuss current trends

More information

Quick Reference Guide

Quick Reference Guide 2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING

More information

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control

More information

NOUVELLLES THERAPIES EN DIABÈTE

NOUVELLLES THERAPIES EN DIABÈTE 1 NOUVELLLES THERAPIES EN DIABÈTE Rémi Rabasa-Lhoret M.D, Ph.D. Endocrinologie Chaire J-A De Sève Professeur agrégé, Département de nutrition, Université de Montréal Directeur Plateforme de Recherche en

More information

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic

More information

DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES

DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:

More information

Curriculum Vitae Eric S. Miguelino, M.D. Staff Toxicologist, Department of Public Health, Food and Drug Branch, State of California

Curriculum Vitae Eric S. Miguelino, M.D. Staff Toxicologist, Department of Public Health, Food and Drug Branch, State of California updated 02/10 Curriculum Vitae Eric S. Miguelino, M.D. Staff Toxicologist, Department of Public Health, Food and Drug Branch, Office Address: Department of Public Health Food and Drug Branch Medical Device

More information

CLINICAL PRACTICE GUIDELINE

CLINICAL PRACTICE GUIDELINE CLINICAL PRACTICE GUIDELINE Procedure: Diabetes Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014 PURPOSE:

More information

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Department Of Biochemistry Subject: Diabetes Mellitus Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Diabetes mellitus : Type 1 & Type 2 What is diabestes mellitus?

More information

Guidelines for the management of hypertension in patients with diabetes mellitus

Guidelines for the management of hypertension in patients with diabetes mellitus Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering

More information

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).

More information

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI

More information